secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2022-10-07T23:59:59+00:00
Accession:  0001193125-22-259636
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 3.02
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology enters amended license deal with Pfizer for ADC platform; pays $8M cash + $10M in stock
--------------------------------------------------------------------------------

- Pyxis pays Pfizer $8M cash and issues ~2.23M shares ($5M) on closing, plus $5M in shares 180 days later.
- Pfizer grants exclusive worldwide rights to FACT platform for ADCs targeting PYX-201 and PYX-203.
- Shares are unregistered, relying on Section 4(a)(2) exemption from the Securities Act.
- Post-issuance, Pyxis had ~35.1M shares outstanding as of October 6, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000119312522259636/0001193125-22-259636-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000119312522259636/d407930d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-259636

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer